Beijing – Boston Scientific Corporation reported clinical endpoint data from the PLATINUM China clinical trial evaluating the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System.  Results of the PLATINUM China trial, a separate arm of the overall PLATINUM trial program sponsored by Boston Scientific, supported the proven safety and effectiveness of the PROMUS Element Stent by demonstrating a low nine-month ARC definite/probable stent thrombosis rate of 0 percent and a 2.2 percent nine-month target lesion revascularization rate.  Results were revealed at 11^th annual scientific sessions of China Interventional Therapeutics (CIT) 2013 in partnership with TCT today in Beijing, China.  The principal investigator of the trial is Professor Gao Runlin from Fuwai Hospital, National Center for Cardiovascular Disease of China, and a member of the Chinese Academy of Engineering.  Professor Han Yaling, a renowned cardiovascular expert from Shenyang Northern General Hospital, was the co-lead researcher and co-principal investigator.

As China’s population continues to age, cardiovascular disease has risen as one of the greatest threats to individual health.  Currently, approximately 230 million people in the country suffer from cardiovascular disease and approximately 3.5 million people die from it each year. According to data released by the cardiovascular interventional diagnosis and treatment management information network of China’s Ministry of Health, in 2011 there were more than 330,000 people receiving coronary artery intervention treatment in China.  However, compared with developed countries, China's operation rate in cardiovascular interventional therapy is still relatively low.

Data, such as results from the PLATINUM China trial, drew more than 5,000 experts from China and around the world to CIT.  Michael F. Mahoney, CEO of Boston Scientific, also attended several activities at the conference.

“As an innovative global leader in the field of coronary intervention, Boston Scientific is dedicated to providing a wide range of high-quality and efficient solutions for customers and patients in China,” said Mahoney.  “Under the leadership of our new management team, our sales in the Chinese market have grown significantly.  I believe our China team will become even more integrated within the Chinese market and will focus on localized research and development—building up long-term strategic relationships and providing effective and appealing products to Chinese patients.”

Since entering the Chinese market in 1997, Boston Scientific has continuously maintained a high performance standard.  In 2012, the company achieved near 50 percent year-on-year growth.  Over the next five years, Boston Scientific expects to invest heavily in China with research and development of products and technology, as well as the education of doctors and patients.  Construction on Boston Scientific’s China Innovation Center, training center and head office in Shanghai is expected to be completed in September.

Source: Boston Scientific Corporation